Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.

about

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.

Item

http://www.wikidata.org/entity/Q55312940

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Construction and characterizat ...... e at picomolar concentrations.

@en

Construction and characterizat ...... e at picomolar concentrations.

@nl

type

Item

label

Construction and characterizat ...... e at picomolar concentrations.

@en

Construction and characterizat ...... e at picomolar concentrations.

@nl

prefLabel

Construction and characterizat ...... e at picomolar concentrations.

@en

Construction and characterizat ...... e at picomolar concentrations.

@nl

P1476

Construction and characterizat ...... ve at picomolar concentrations

@en

P2093

Alberto Luis Epstein

http://www.w3.org/2001/XMLSchema#string

Ana Carolina de Carvalho

http://www.w3.org/2001/XMLSchema#string

André Lopes Carvalho

http://www.w3.org/2001/XMLSchema#string

Anna Luiza Silva Almeida Vicente

http://www.w3.org/2001/XMLSchema#string

Lidia Maria Rebolho Batista Arantes

http://www.w3.org/2001/XMLSchema#string

Matias Eliseo Melendez

http://www.w3.org/2001/XMLSchema#string

Renato José Silva-Oliveira

http://www.w3.org/2001/XMLSchema#string

P2860

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

Apoptosis control by death and decoy receptors.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Corpse clearance defines the meaning of cell death.

Apo2L/TRAIL and its death and decoy receptors.

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model.

Death receptor agonists as a targeted therapy for cancer.

P304

27233-27241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25519

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Rui Manuel Reis

P577

2018-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29930761

http://www.w3.org/2001/XMLSchema#string

P932

6007462

http://www.w3.org/2001/XMLSchema#string